Direct to consumer (DT C) prescription drug advertising is one of the fastest
Direct to consumer (DT C) prescription drug advertising is one of the fastest growing categories of advertising. Expenditures have increased from about $25 million in 1992 to nearly $2 billion in 1999. Given strong evidence of consumerdriven demand for advertised prescription drugs, research was conducted to assess the extent to which DT C prescription drug advertising provides consumers with the information they need to make an informed evaluation of an advertised drugÏs relative beneÐts and risks. T wo studies explored the relationship between the completeness of the statement describing drug-associated side e †ects (the ""risk statementÏÏ) and consumersÏ perceptions of a drugÏs safety and appeal. T he research manipulated risk statement completeness with regard to the incidence levels of side e †ects mentioned in the statement (which in turn a †ected the number of side e †ects mentioned) and the presence or absence of a numeric indicator of side e †ect incidence. T he research strongly suggests a direct relationship between risk statement completeness and consumersÏ perceptions of drug safety and appeal. Consumers rate the safety and appeal of drugs described with an incomplete risk statement signiÐcantly more positively than comparable drugs described with a more complete risk statement. Implications of the research for the regulation and presentation of DT C prescription drug advertising and advertiser communication practices are discussed.
One of the fastest growing forms of consumer advertising is DTC prescription drug advertisingÈa pharmaceutical companyÏs presentation of prescription drug information to the general public through consumer-oriented media (Pierpaoli, 1986) . Media expenditures for DTC prescription drug advertising have increased nearly twenty-fold during the 1990s, growing from about $25 million in 1992 to almost $1.9 billion dollars in 1999 (Okie, 2000) . Moreover, advertising expenditures are expected to continue to increase because of recent Food and Drug Administration (FDA) regulatory changes. The FDA has Ðnalized guidelines for radio and television prescription drug advertising, which allows advertisers to describe their drugÏs beneÐts without providing long, detailed descriptions of the drugÏs side e †ects (FDA, 1999) .
Sales of advertised prescription drugs often increase dramatically after the introduction of DTC advertising (Liebman, 2000) . Claritin, for example, was the leading prescription drug advertiser in the Ðrst half of 1998 and, in that time period, its sales rose 32%. Allegra and Zyrtec, also heavy advertisers, saw sales rise 100% and 56%, 350 J. J. Davis respectively (Freudenheim, 1998) . Importantly, in spite of the fact that an advertised drug must be prescribed by a physician, evidence suggests that the rise in sales of DTC advertised prescription drugs is consumer driven. Five related trends help to explain how DTC advertising a †ects product sales : levels of advertising increase consumersÏ awareness of prescription drugs and n High the conditions that they treat. A recent survey conducted by the National ConsumerÏs League found that nearly 80% of consumers say that they are aware of prescription drug advertising (Brody, 1998) and the average consumer recalled seeing ads for Ðve di †erent prescription drugs (Center for Drug Evaluation and Research, 1999) . leads consumers to talk with their doctors about advertised conditions. n Awareness
Patient visits have increased most rapidly in areas related to the conditions treated by the most heavily advertised DTC drugs. In the seven most heavily advertised groups of DTC products (cholesterol, smoking cessation, osteoporosis, hair loss, ulcers, postmenopausa l problems, and depression) patient visits increased 22% versus a 2% overall patient increase when compared with the prior year (Freudenheim, 1998 ; Holmer, 1999) . physician visits, consumers take the initiative in requesting the advertised n During drug. High levels of drug advertising awareness is associated with a greater likelihood of requesting a speciÐc drug (Peyrot, Alperstein, Van Doren, & Poli, 1998) . Eighty percent of adults say they would be likely to talk with their doctor if they saw an advertisement for a drug that treated a condition that was bothering them (CDER, 1999) . This predisposition may explain the results of the IMS Health survey of 2,500 physicians, which found that more than half of all physicians (53%) reported a ""signiÐcant increaseÏÏ in patients requesting drugs by brand name. Importantly, this increase appears to be related to the impact of DTC advertising. are more likely to request highly advertised drugs. Survey research has n Consumers linked advertising expenditures and drug requests. Two of consumersÏ most requested drugs (Claritin and Allegra) are also the most heavily advertised (Hollon, 1999) . Moreover, the 10 most heavily advertised drugs (in 1998) account for 22% of the total increase in spending by consumers for all drugs between 1993 and 1998 (Zendle, 1999) . donÏt give up. Most consumers are successful in obtaining the requested n Consumers drug. Survey data estimate that between half and three-quarters of all requests are approved by a physician (Brody, 1998 , ""National Survey,ÏÏ 1998 . Moreover, there are indications that consumers who are unable to obtain an advertised drug from their own physician meet the denial with ""suspicion and hostilityÏÏ (Neergaard, 1999) and ""shop aroundÏÏ until they Ðnd a physician willing to prescribe the desired drug (Cohen, 1990 ; She †et & Reece, 1994) .
Marketplace data show that DTC prescription drug advertising has a †ected how consumers perceive, request, and obtain prescription drugs. However, to what extent does this advertising allow consumers to evaluate accurately the risks and beneÐts associated with alternative, competing drugs and to develop appropriate brand requests and preferences ? This question is important, as research has shown that consumers are more likely to make unsound medical decisions when they have incomplete or imperfect knowledge of the risks and beneÐts associated with alternative options (Viscusi, Magat, & Huber, 1986) . We examine one advertiser practiceÈ the completeness or lack of completeness of the risk information presented in DTC Risk Statement Completeness 351 prescription drug advertisingÈand the e †ect of this practice on consumersÏ perceptions of drug safety and drug preference. The exploration of this issue extends prior research on consumersÏ awareness of and reactions to DTC prescription drug advertising (see, for example, Alperstein & Peyrot, 1993 ; Everett, 1991 ; Perri & Dickson, 1988 ; Perri & Nelson, 1987) and is conducted within the context of the FDAÏs approach to the regulation and evaluation of DTC drug advertising.
DTC Prescription Drug Advertising Regulation and Risk Statement Completeness
The content of DTC prescription drug advertisements is governed by regulations issued by the FDA. The FDA examines prescription drug advertising to make certain that from a content perspective the advertisement is not deceptive, misleading, or does not in other ways violate any applicable rules and regulations. FDA regulations list 33 ways in which any prescription drug advertisement may be false or misleading (Code of Federal Regulations, 1997) . Beyond these criteria that apply to all DTC drug advertisements, product-speciÐc print advertisements, that is, advertisements that mention the drugÏs name and present information on the drugÏs potential beneÐts, safety, side e †ects, and risk, are considered deceptive or misleading if they fail to present fair balance within the text of the advertisement.
Fair balance is one of the most important aspects of the FDAÏs prescription drug advertising regulations. Here, the FDA examines an advertisement to determine if it presents an unbiased and balanced account of the risks and beneÐts associated with drug usage. From the perspective of the FDA, a product-speciÐc advertisement fails to present a fair balance between information relating to side e †ects and contraindications and information relating to e †ectiveness of the drug in that the information relating to e †ectiveness is presented in greater scope, depth or detail . . . and this information is not fairly balanced by a presentation of a summary of true information relating to side e †ects and contraindications of the drug. (Code of Federal Regulations, 2000, p. 76) Fair balance, therefore, requires that a DTC prescription drug print advertisement present a balance of risk and beneÐt information within the context of the advertisement. Risk information typically is presented in a risk statement, a one or two sentence presentation of the side e †ects associated with drug usage. The FDAÏs regulations governing prescription drug advertising do not specify the speciÐc form or content of the risk statement and, as a result, advertisers have considerable latitude in the form and content of the side e †ects reported in a DTC drug advertisementÏs risk statement. Advertisers must present a balance of drug beneÐts and risks (side e †ects). T hey are, however, under no compulsion to report all of side e †ects or to even report all major side e †ects.
What then is the relationship between fair balance and completeness in the reporting of side e †ects ? From a content perspective, completeness in side e †ect reporting is not a speciÐed and explicit component of the FDAÏs fair balance criterion. Advertisers can satisfy the FDAÏs fair balance criterion and still present incomplete risk information, for example, by omitting a relatively high incidence side e †ect or failing to present a fair and representative listing of all side e †ects. But does the presentation of side e †ects in this manner really achieve ""fair balance ?ÏÏ We argue that (1) fair balance is only achieved when a consumer, upon reading or seeing a DTC prescription drug advertisement, clearly understands his or her likelihood of su †ering drug-related side e †ects and is able to place the risk of these side e †ects in the context of anticipated drug-related beneÐts and that (2) this understanding is achievable only when a risk statement presents a complete description of the risks associated with a particular drugÏs usage.
The argument that fair balance requires a complete (or at least more complete) disclosure of risk information is predicated on the assumption that consumer attitudes toward an advertised drug are a †ected by the completeness of the risk statement. If attitudes toward drug safety, beneÐts, and appeal are a †ected by risk disclosure completeness, then an argument can be made that fair balance is not achieved in the context of incomplete risk statements. On the other hand, if consumer attitudes are not a †ected by the characteristics of the risk statement, that is, if attitudes toward the advertised drug are the same when confronted with complete and incomplete risk statements, then the issue of completeness becomes less signiÐ-cant.
There is no commonly accepted deÐnition of ""completenessÏÏ with regard to DTC prescription drug advertising risk statements nor is there a consensus as to a methodological approach for exploring the e †ects of completeness on consumersÏ attitudes toward the advertised drug. As a result, this paper presents the results of two empirical studies that explore the relationship of risk statement completeness and subsequent attitudes toward an advertised drug. Each study provides a di †erent operational deÐnition of ""complete risk statementÏÏ and utilizes a di †erent methodological approach. Both studies seek to answer the question : ""To what extent does the completeness of side e †ect reporting a †ect consumer perceptions of drug safety and drug preference ?
Methods : Study One
Study One examined the e †ect of specifying a minimal reporting level for drugrelated side e †ects on consumersÏ preference for an advertised prescription drug. The speciÐcation of this level, in this study, was identiÐed through qualitative research. Individual interviews were conducted with 37 undergraduat e and graduate students at a major western university. These students (who ranged in age from 22 to 43) indicated that an incidence level of 3% was considered their baseline of concern. Most said that they were concerned and wanted to know about drug-related side e †ects occuring at a rate of 3% or greater ; most were not concerned about side e †ects occurring at less than a 3% level of incidence. As a result, a complete risk statement was deÐned operationally in this study as ""a statement that presented all drug-related side e †ects occurring at a rate of 3% or greater.ÏÏ Finally, in terms of setting a minimal level of side-e †ect concern, it should be noted that although the generalizability of these studentsÏ responses is limited given their nonrandorn selection, the consistency of their responses nevertheless provides sufficient direction for the setting of a minimal level of concern with regard to side e †ect incidence.
Creation of Complete and Incomplete Risk Statements
ReÑecting the studyÏs operational deÐnition of ""risk statement completeness,ÏÏ two di †erent risk statements were developed for each of eight drugs that, at the time of the research, were appearing in DTC prescription drug advertisements.
The Ðrst risk statement (for analytical purposes labeled the ""incomplete risk statementÏÏ) was taken directly from the drugÏs DTC advertisement and as a result reÑected current advertiser practice. Incomplete risk statements always presented a subset of all potential side e †ects, and in all cases, not all side e †ects at or above the 3% criterion were presented. A typical incomplete risk statement was, ""Like any prescription drug, Fosamax may cause side e †ects. The most common side e †ects are: stomach and muscle, bone or joint pain.ÏÏ The second risk statement for each drug (for analytical purposes labeled the ""complete risk statementÏÏ) was identical to the Ðrst except that all side e †ects occurring at an incidence of 3% or more were included in the description. These side e †ects were identiÐed from data provided in the brief summary that accompanied each drugÏs DTC advertisement. The complete risk statement for Fosamax was Like any prescription drug, Fosamax may cause side e †ects. The most common side e †ects are: stomach and muscle, bone, or joint pain. Other, less frequently reported side e †ects are nausea, heartburn, irritation or pain of the esophagus (the tube that connects your mouth to your stomach), vomiting, difficulty swallowing, a full or bloated feeling in the stomach, constipation, diarrhea, and gas. In clinical trails involving patients with thick, hard, yellowish and/or brittle nails, the following adverse e †ects led to either a temporary or permanent discontinuation of treatment : elevated liver enzymes, gastrointestina l disorders, and rash. Complete Risk Statement
In clinical trials involving patients with thick, hard, yellowish and/or brittle nails, the following adverse e †ects led to either a temporary or permanent discontinuation of treatment : nausea, vomiting, diarrhea, edema, fatigue, headache, elevated liver enzymes, and rash. Like any prescription drug, Fosamax may cause side e †ects. The most common side e †ects are: stomach and muscle, bone, or joint pain. Other, less frequently reported side e †ects are nausea, heartburn, irritation or pain of the esophagus (the tube that connects your mouth to your stomach), vomiting, difficulty swallowing, a full or bloated feeling in the stomach, constipation, diarrhea and gas.
Each incomplete and complete risk statement was preceded by an identical product description. This description named the drug and provided a brief overview of the condition treated by the drug and the drugÏs major beneÐt(s). The product description for Fosamax was Fosamax is a prescription drug that helps treat osteoporosis. Osteoporosis is caused when women lose bone mass faster than it is replaced. During the Ðve years after menopause, some women may lose at much as 25% of their bone density. Fosamax is a treatment thatÏs non-hormonal and proven to restore lost bone in many women past menopause.
The product descriptions and risk statements for each of the eight drugs used in Study One are shown in Table 1 .
Questionnaire
It was believed that one potential source of bias might be related to the overall length of the risk statement. Since complete risk statements were always longer than incomplete risk statements, the mixing of incomplete and complete risk statements in the same questionnaire potentially could draw attention to the shorter, incomplete descriptions. As a result, all complete risk statements appeared on one questionnaire and all incomplete risk statements appeared on a second questionnaire. The order of drug presentation within the questionnaires was determined by a random drawing ; the Ðnal order of presentation was identical for both forms of the questionnaire.
M easure
Each product description (on both questionnaires) ended with the following question : ""If you or someone you know had [name of medical problem from product description inserted here] how likely or unlikely would you be to recommend or purchase [name of drug inserted here]?ÏÏ This question was followed by a seven-point Likert scale with endpoints of ""Extremely likely to recommend or purchase [name of drug]ÏÏ and ""Extremely unlikely to recommend or purchase [name of drug].ÏÏ Several aspects of this measure merit noting.
use of ""recommend or purchaseÏÏ increased the relevance of the question to n The each respondent. Although some members of the sample were unlikely to exhibit a particular described medical condition, all members of the sample conceivably could be in the position of knowing someone with the condition, and thus might be in the position of recommending the advertised drug. or purchaseÏÏ goes to the core of the Federal Trade CommissionÏs n ""Recommend (FTCÏs) approach to advertising regulation, the measurement of materiality, which is the ""extent to which a representation, omission or practice inÑuences consumer behavior or purchasing patternsÏÏ (FTC, 1983) . or purchaseÏÏ provides an easy-to-evaluat e summary measure of n ""Recommend drug perceptions.
Procedure
Respondents completed each questionnaire individually. Recruited respondents were taken to a small interview room and were asked to read the questionnaire directions and complete the questionnaire. The questionnaire directions read, ""Please read each question and answer as instructed. There is no right or wrong answer to each question.ÏÏ Respondents were given an unlimited amount of time to complete the questionnaire, which they gave to a trained interviewer upon completion. Questionnaires were checked for completeness and problem questionnaires (three in this study because of missing data) were returned to the respondent for revision.
Results
Demographic Characteristics. The sample for Study One consists of 140 adults recruited via mail intercept. No incentive was o †ered for study participation. Seventy-Ðve adults responded to the questionnaire containing incomplete risk statements, and 65 responded to the questionnaire that contained the complete risk statements. Importantly, there were no signiÐcant di †erences in demographics between the two versions of the questionnaire (see Table 2 ). The samples for both questionnaires consisted of approximately equal numbers of men and women with a broad range of education, age, and income. The results of chi-square tests comparing the demographics of the two questionnaires were as follows : gender, chi square 5 1.8, p 5 n.s., df 5 1 ; education, chi square 5 4.3, p 5 n.s., df 5 5 ; income, chi square 5 9.4, p 5 n.s., df 5 6. A t test for age was also not signiÐcant (t 5 1.85, (Table 3 ). In seven of the eight cases, consumers were signiÐcantly more likely to ""recommend or purchaseÏÏ a drug when the drugÏs description was accompanied by an incomplete versus complete risk statement (all p values were .05 or less). The eighth case showed no di †erence between the two descriptions (p 5 .11) although the direction of the mean scores was consistent with the prior seven cases ; that is, consumers were more likely to ""recommend or purchaseÏÏ the drug when the drugÏs description was accompanied by an incomplete versus complete risk statement.
Risk statement completeness, however, did not a †ect directionality of response as all mean ratings were greater than the neutral midpoint of the scale ; that is, all mean ratings indicated a positive likelihood to recommend or purchase. Thus, a Seven-point scale with endpoints of 1 5 ""Extremely likely to recommend or purchaseÏÏ to 7 5 ""Extremely unlikely to recommend or purchase.ÏÏ regardless of risk statement completeness, respondents indicated that they were more rather than less likely to purchase or recommend a described drug.
Discussion
Study One demonstrated that adoption of a 3% base level for side e †ect reporting has a signiÐcant e †ect on a drugÏs appeal, as measured by consumersÏ rating of their likelihood to recommend or purchase the drug. This Ðnding is intuitively reasonable. Drugs that have more side e †ects should be less appealing than drugs with a greater number of associated side e †ects. However, although the more complete risk statements resulted in relatively lower intent to recommend or purchase versus the incomplete descriptions, the absolute level of intent to recommend or purchase nevertheless was unexpected. It might be expected that consumersÏ ratings of drugs with fewer side e †ects (i.e., the incomplete risk statements) would fall above the neutral scale point on the ""recommend or purchaseÏÏ rating scale, whereas the ratings of drugs with more side e †ects (i.e., the complete risk statements) would fall below the neutral scale point. This was not the case.
The signiÐcant di †erences in consumersÏ reactions to complete and incomplete side e †ect descriptions (as evidenced in this study) lend support to the belief that completeness in side e †ect reporting does a †ect drug perceptions and preference. However, given the Ðnding that all described drugs were likely to be recommended or purchased, an attempt was made to identify those factors that might have inÑu-enced consumersÏ positive responses. IdentiÐed explanations relate to consumersÏ mind-set and methodology.
One reviewer pointed out that consumersÏ mind-set with regard to advertised drugs may be one contributing factor to the pattern of response. Consumers may have reacted positively to all advertised drugs in this study because they believe that a drug must be ""goodÏÏ if it is allowed to be advertised. Thus, it would be appropriate to recommend or purchase any advertised drug ; the only evaluation needed would be to identify the drug that may be the ""bestÏÏ among all acceptable choices. We believe that this is an intuitively plausible identiÐcation of one contributing factor, supported by recent survey data that indicate that about half of consumers believed that DTC ads must receive government approval prior to display and 43% of consumers believe that only ""completely safeÏÏ drugs are allowed to be advertised (Bell, Kravitz, & Wilkes, 1999) .
Although consumersÏ mind-set may have played a role in the pattern of results, we believe that methodological issues also may have contributed. As a result, we focused our e †orts on identifying methodological aspects of Study One that may have increased the likelihood of all drugs being recommended or purchased. Two aspects of the methodology were identiÐed : each of the prescription drugs were presented in isolation ; that is, there was n First, no ""head-to-headÏÏ comparison of the same drug when presented with a complete and an incomplete description. Without this comparison, respondents may have assumed that all advertised drugs were safe and therefore conÐdently could be ""recommended or purchased.ÏÏ all side e †ects were preceded by an imprecise frequency descriptor (Maat n Second, & Klaasen, 1994 ; Toogood, 1980) , that is, words such as ""some,ÏÏ ""many,ÏÏ and ""fewÏÏ rather than an absolute numeric descriptor. In the absence of numeric levels of incidence, consumers in Study One might have assumed that regardless of the number of side e †ects listed in the risk statement, the absolute likelihood of exhibiting any particular side e †ect was low. Beyond the ambiguity of imprecise frequency descriptors, consumersÏ assumption that all side e †ect levels were low may have been facilitated by some of the copy used in the risk statements, for example, ""Though most users experience trouble-free relief,ÏÏ other, less frequently reported side e †ects are, ""and while most people tolerate Relafen well. . . .ÏÏ If consumers made either of the prior assumptions, then the results of Study One appear more understandable . However, to help resolve the issue of why all drugs received positive ratings regardless of risk statement completeness, Study Two explored the e †ects of risk statement completeness from a di †erent methodological perspective.
Methods : Study Two
Study Two examined the e †ect of risk statement completeness with a methodology that addresses some of the potential underlying reasons for the overall positive perceptions of all described drugs in Study One. The changes in Study Two related to drug comparisons, minimal levels of side e †ects reported, and the presence of numeric information :
comparisons. Study Two presented paired comparisons of drugs. The same n Drug respondent was given a complete and incomplete risk statement for di †erent drugs that provided the same health beneÐt. This ""head-to-headÏÏ comparison allowed consumers to compare directly drugs with the same beneÐts but with di †erent sets of associated risks. levels of side e †ect reported. As discussed earlier, advertisers have the n Minimal latitude to choose the side e †ects reported in the risk statement. Study One set a minimal level of reporting (3% incidence or higher). Study Two operationalized ""completenessÏÏ from the advertiser perspective and permitted each advertiser to set the minimal level of reported side e †ects. A complete risk statement in this study was deÐned as ""a statement that contains all side e †ects with an incidence greater Nevo is a prescription drug product that helps treat runny noses. The potential side e †ects associated with Nevo are : headache (10%), upper respiratory tract infections (10%), mild nose bleeds (9%), sore throat (8%), and nasal dryness (5%).
Case 2
Incomplete Description Tarlex is a prescription drug product that helps with genital herpes. The potential side e †ects associated with Tarlex are : nausea (15%), headache (14%), diarrhea (5%), and dizziness (3%).
Complete Description
Reval is a prescription drug product that helps with genital herpes. The potential side e †ects associated with Reval are : nausea (15%), headache (14%), vomiting (6%), diarrhea (5%), constipation (4%), abdominal pain (3%), and dizziness (3%).
Case 3
Incomplete Description Oliva is a prescription drug product for breast cancer therapy. The potential side e †ects associated with Oliva are : hot Ñashes (48%), vaginal discharge (30%), and irregular menses (25%).
Complete Description
Nadex is a prescription drug product for breast cancer therapy. The potential side e †ects associated with Nadex are : hot Ñashes (48%), weight gain (38%), Ñuid retention (32%), vaginal discharge (30%), nausea (26%), and irregular menses (25%).
Case 4
Incomplete Description Prava is a prescription drug product that helps prevent a Ðrst heart attack. The potential side e †ects associated with Prava are : slight rash (4%) and mild upset stomach (3%).
Complete Description
Choval is a prescription drug product that helps prevent a Ðrst heart attack. The potential side e †ects associated with Choval are : localized musculoskeletal pain (10%), common cold (7%), nausea/vomiting (7%), headache (6%), diarrhea (6%), abdominal pain (5%), constipation (4%), fatigue (4%), general chest pain (4%), cardiac chest pain (4%), slight rash (4%), rhinitis (4%), dizziness (3%), and mild upset stomach (3%).
TABLE 4 Continued

Case 5
Incomplete Description Larit is a prescription drug product for children that helps relieve seasonal allergy symptoms. The potential side e †ects associated with Larit are : hyperactivity (3%) and drowsiness (2%).
Complete Description
Claris is a prescription drug product for children that helps relieve seasonal allergy symptoms. The potential side e †ects associated with Claris are : nervousness (4%), hyperactivity (3%), wheezing (4%), and drowsiness (2%).
than or equal to the side e †ect with the lowest incidence mentioned in the advertiser created risk statement.ÏÏ of numeric information. Numeric incidence levels accompanied all n Presence reported side e †ects.
Each of these aspects of Study Two are reÑected in the experimental materials.
Creation of Complete and Incomplete Risk Statements
Two di †erent risk statements were developed for each of Ðve drugs advertised in DTC prescription drug ads. The Ðrst risk statement (for analytical purposes labeled the ""incomplete risk statementÏÏ) was taken directly from the drugÏs DTC advertising. In all cases, these descriptions presented a subset of all potential risks and side e †ects. A second risk statement for the drug (for analytical purposes labeled the ""complete risk statementÏÏ) presented a more complete description. Here, reÑecting this studyÏs operational deÐnition of completeness, all side e †ects with an incidence level greater than or equal to the lowest incidence level in the advertiser-created description were included. Numeric descriptors accompanied all side e †ects in both risk statements. Both incomplete and complete risk statements were preceded by a brief description of the condition treated by the drug and the drugÏs primary beneÐt(s). Finally, because consumers were asked to make "head-to-headÏ comparisons, a Ðctitious name was given to each of the described drugs. The risk statements for each of the Ðve drugs used in this study are shown in Table 4 .
Questionnaire
The Ðve-page questionnaire contained Ðve sets of paired product descriptions, one set presented on each page. In the development of the questionnaire, a coin toss determined the ordering within each pair of descriptions, that is, whether the complete or incomplete risk statement was presented Ðrst. The random ordering of descriptions within each pair was done to reduce presentation order bias, that is, having complete or incomplete descriptions appear in the same order across the entire questionnaire.
M easures
Two measures followed each set of paired product descriptions. The Ðrst measure assessed perceptions of product safety and read as follows : .000 a n 5 58. b Ten-point scale where 0 5 ""Not at all safeÏÏ and 9 represents ""extremely safe.ÏÏ On a scale of 0 to 9, where 0 means ""not at all safeÏÏ and 9 means ""extremely safe,ÏÏ how would you rate the safety of each drug ? I would give [insert name of drug from Ðrst description] a rating of . I would give [insert name of drug from second description] a rating of .
The second measure, similar to Study One, asked each respondent to make a judgment related to drug recommendation or purchase. Respondents were asked to select (from among the two described drugs) the one that they would recommend or purchase, as follows :
If I were to purchase or recommend a drug for treating [insert name of medical condition], I would choose (place an X by the drug you would choose) : (Name of drug from Ðrst product description) (Name of drug from Ðrst second description)
Procedure
Respondents completed each questionnaire individually. Recruited respondents were taken to a small interview room and were asked to read the survey directions and complete the survey. Respondents were given an unlimited amount of time to complete the survey, which was given to a trained interviewer upon completion. Surveys were checked for completeness. Two problem questionnaires (more than one item checked on the personal recommendation scale) were returned to the respondent for revision.
Results
Demographic Characteristics. The sample for Study Two consisted of 58 adults recruited via mall intercept. No incentive was o †ered for study participation. Similar to the sample of Study One, the sample for Study Two (Table 2) consisted of approximately equal numbers of men and women with a broad range of education, age, and income. Table 5 presents the mean safety ratings for each of Ðve drugs when the drugÏs description is accompanied by an incomplete and complete risk statement. Table 5 also presents the results of t tests comparing these means. With regard to the absolute level of mean scores, level of completeness a †ected perceptions of drug safety. Mean scores for drugs described with the incomplete description always fell on the positive (i.e., ""more safeÏÏ) end of the rating scale, whereas the mean scores for drugs presented with the complete description fell on the neutral to negative (i.e., ""less safeÏÏ) end of the scale. Di †erences all were statistically signiÐcant (t tests were all signiÐcant at p < .001) ; drugs described with incomplete descriptions of side e †ects always were rated as more safe.
E †ect of Risk Statement Completeness on Perceptions of Product Safety and Appeal.
Given this pattern of response, it is not surprising that respondents signiÐcantly were more likely to recommend or purchase a drug described with an incomplete risk statement (Table 6 ). Across all Ðve drug pairings, a minimum of three-quarters of the sample preferred the drug presented with an incomplete description of side e †ects. Chi-square tests indicate that levels of preference were, in all cases, signiÐ-cantly di †erent than chance, that is, a preference of 50% (all p < .001).
Discussion
DTC prescription drug advertising has polarized the medical community. Some argue that DTC advertising is ""an excellent way to meet the growing demand for medical information, empowering consumers by educating them about health conditions and possible treatmentsÏÏ (Holmer, 1999) . Similarly, an FDA/Prevention Magazine research study concluded that Many consumers who have seen advertisements for medicines they are currently taking say the advertising makes them feel better about the medicine theyÏre taking, makes them more likely to take their medicine and reminds them to have their prescriptions reÐlled. [These outcomes] may play a very real role in enhancing public health. ""National Survey,ÏÏ 1998) Others argue that DTC drug advertising undermines the patientÈphysician relationship (Hollon, 1999) , increases the likelihood of overmedication, increases consumersÏ preference for drug versus other therapies, increases consumersÏ demand for more expensive drug treatments versus other treatment options, and wastes the time of both patients and doctors (Brody, 1998 ; Freudenheim, 1998) . Ho †man and Wilkes (1999) summarized this point of view when they stated that DTC advertisements ""are intended not to educate patients, nor to empower them to be more intelligently involved in their own care, but merely to increase physician prescribing, regardless of need (p. 1301).ÏÏ We believe that DTC drug advertising has the potential to serve the public good. In addition to the reasons articulated earlier in support of DTC advertising, consumers need the information presented by DTC advertising because ""managed care makes healthcare less personal and also imposes greater demands on patients to keep track of their own medical needsÏÏ (Pines, 1997, p. 65 ). But we believe also that the potential beneÐts of DTC advertising have not yet been realized because of the poor quality of information presented in the advertising. According to the FDA/ Prevention Magazine research study only 28% of the people who viewed DTC ads felt strongly that they were educated about the risks and beneÐts of prescription drugs, and a majority (55%) felt the ads made the drugs appear harmless (""National Survey,ÏÏ 1998). In sum, because consumers need ""more and better information to maintain good healthÏÏ (Pines, 1997) , the potential beneÐts of DTC drug advertising will be realized only when the information communicated by the advertisements provides a sound basis for helping consumers understand (a) the most appropriate circumstances for drug usage and (b) the beneÐts and risks associated with drug usage.
The FDA/Prevention Magazine Ðnding that a majority of consumers believe that DTC advertising makes the advertised drugs appear harmless is directly related to the outcome of this research. (""National Survey,ÏÏ 1998). Studies One and Two explored the relationship between the completeness of the statement describing drug-associated side e †ects and consumersÏ perceptions of that drugÏs safety and appeal. Although the Ðndings need to be tempered by two study limitations (relatively small sample sizes and the fact that not all respondents were in a drugÏs target audience), the research strongly suggests that there is a direct relationship between completeness in side e †ect reporting and consumersÏ perceptions of drug safety and appeal. Studies One and Two explored this relationship from di †erent perspectives and methodological approaches, yet the fundamental Ðnding of both studies was the same : Consumers rate the safety and appeal of drugs described with an incomplete disclosure of side e †ects signiÐcantly more positively than comparable drugs described with more complete side e †ect disclosure. It appears, therefore, that advertisersÏ presentation of incomplete risk statements do not allow consumers to evaluate adequately drug risks and beneÐts and, as a result, prevent the positive potential of DTC drug advertising from being realized.
It is important to note that the inaccurate conclusions many consumers draw from incomplete risk statements (with regard to drug safety and appeal) likely are to become even more problematic as DTC advertisers change the form and content of the brief summary that accompanies print DTC drug ads. In the past, the brief summary presented tables and text that fully described the range and levels of drugassociated side e †ects so that those (likely few) consumers who desired could Ðnd out the ""full story.ÏÏ Brief summaries recently have changed to be more consumer friendly. New, revised brief summary content typically eliminates data tables and complete descriptions of drug-related side e †ects. As a result of these changes, all consumers are unable to determine whether the risk statement accurately communicates the range and breadth of drug-related side e †ects.
Implications for the Regulation of DTC Prescription Drug Advertising
We believe that the research Ðndings, consistent across both studies, provide clear support for a reexamination of what constitutes ""fair balanceÏÏ in DTC prescription drug advertising. Fair balance is, and should be, an important component of DTC prescription drug advertising. Fair balance is required because the FDA seeks to maximize the chances that consumers are able to make a fair, informed, and reasonable evaluation of an advertised drugÏs safety and appeal, and this type of evaluation can occur only if consumers have a complete understanding of the advertised drugÏs beneÐts and risks. This research suggests that the latitude currently accorded DTC drug advertisers prevents the goal of fair balance (and informed evaluations) from consistently being achieved. As demonstrated in the research , it is entirely possible for consumers to draw false conclusions from DTC drug advertising, for example : equivalent drugs (with equivalent beneÐts and risks) may be perceived di †er-n Two entially by consumers because of di †erences in the number of side e †ects presented in their risk statements. may appear to be safer then they actually are because of the number and n Drugs types of side e †ects included in their risk statement.
The research strongly suggests that consumers might well be at risk given the FDAÏs current approach to the evaluation of fair balance; consumers are making decisions and requesting drugs from their physicians based on incomplete information and false perceptions of relative drug safety. The trend at the FDA is for a loosening of regulations governing DTC prescription drug advertising, as evidenced in the 1997 revision of guidelines for television advertising. The research Ðndings suggest that this is the wrong direction to take at this time. Consumers appear determined to take a more active role in their health care decisions. For these decisions to be informed, consumers need accurate, meaningful, and complete information. We agree with Hollon (1999) , who states, ""Providing poor quality information in todayÏs marketplace of health information results in little or no beneÐt for the public.ÏÏ (p. 383)
Implications for Advertiser Practice
Until the FDA revises its ""fair balanceÏÏ regulations, consumers must rely upon advertiser self-regulation for improvements in the content and communication of DTC drug advertisements. The argument can be made that social and ethical considerations require such self-regulation.
Incomplete risk statements can be considered unethical advertiser behaviors if they are found to violate any of the well-accepted moral (as opposed to legal) criteria commonly applied to business (in general) and advertising (in particular). Here are two relevant principles (Feiser, 1996) and their application to DTC prescription drug advertising :
principle : Business should avoid causing unwanted harm. In the context of n Harm DTC prescription drug advertising, this principle applies to both an advertiserÏs business competitors and to consumers. Imagine two drugs that work identically and that have the same set of side e †ects. One drug is advertised with an incomplete risk statement and the second is advertised with a complete risk statement. Harm (through loss of sales) is done to the second drugÏs advertiser if consumers prefer the Ðrst drug over the second because of the di †erence in the number and types of side e †ects reported in each drugÏs risk statement. Psychological and physical harm also can be done to consumers should they request the Ðrst advertised drug over the second thinking that they can avoid some of the side e †ects associated with the second drug but then experience some of side e †ects not noted in the Ðrst drugÏs incomplete risk statement. These decisions would neither be rational nor responsible because the decisions were made on the basis of incomplete information. Violations of this principle would be important especially as research has shown that consumers are more likely to make unsound medical decisions when they have incomplete or imperfect knowledge of the risks and beneÐts associated with alternative options (Viscusi, Magat, & Huber, 1986) . Importantly, although some might believe that an appeal to advertiserÏs ethics likely is to be unproductive, it is encouraging to note that advertisers in the highest levels of advertising agency management appear willing to incorporate ethical considerations in their advertising decision-making process (Davis, 1994) .
Limitations of the Research and Implications for Further Research
The research Ðndings provide consistent initial evidence of how the FDAÏs fair balance criterion can fail to protect consumers from incomplete risk statements. However, the limitations of the current research, coupled with the issues raised by the research, necessitate further research in the area.
One set of further research activities should address methodological issues. First, the relatively small, nonrandom sample in this research limits the strength of conclusions and lowers generalizability to the broader population. Further research will not only want to explore issues raised with more generalizable samples but additionally will want to select samples that permit reliable analyses of important subpopulations, for example, individuals in di †erent demographic groups, individuals with varying experience with DTC prescription drug advertising, and individuals with varying experience with both advertised and nonadvertised prescription drugs. Second, the current research used a nonrandom sample to set a minimal level of consumer concern with drug-associate d side e †ects. Although the research showed that this level did di †erentially a †ect consumersÏ responses to risk statements, further research is needed that will identify more systematically minimal levels of concern. Such research could determine, for example, if there is a minimal level of concern across all conditions treated by DTC prescription drugs or if a minimal level of concern varies across conditions.
Beyond methodology, a second set of research is needed to improve our understanding of the process by which consumers perceptions and attitudes are a †ected by DTC advertising and risk statements. Further research is needed to help better deÐne ""risk statement completeness.ÏÏ The two studies presented in this paper highlight the complexity of this issue, for example :
""completenessÏÏ be deÐned in terms of the number of side e †ects reported ? n Should In terms of a minimum incidence level ? In terms of the most common side e †ects ? (And how is ""most commonÏÏ deÐned ?)
""completenessÏÏ require numeric indicators in the risk statement ? For n Does example, is the statement, ""The major side e †ects are headache and nauseaÏÏ equivalent in terms of completeness with the statement, ""The major side e †ects are headache (66%) and nausea (45%) ?ÏÏ
We encourage research that explores the issues of ""completenessÏÏ and ""fair balanceÏÏ from the consumersÏ, rather than simply a content analysis, perspective. In addition, the current research used single measures (""recommend or purchase,ÏÏ ""safetyÏÏ) to evaluate consumersÏ drug perceptions after exposure to complete and incomplete risk statements. Although there were methodological advantage s to using single summary measures, one drawback of these measures was that they did not permit an in-depth exploration of why responses to these measures varied as a result of risk statement completeness. Therefore, further research is required that will assess reactions to risk statements that measure speciÐc dimensions of ""safetyÏÏ and that probe the range of reasons why a particular drug is or is not ""purchased or recommended.ÏÏ
Conclusion
There is little doubt that DTC prescription drug advertising will continue to increase. We believe that DTC prescription drug advertising is only in the consumer interest if it is constructed and presented in a way that helps consumers fully understand an advertised drugÏs beneÐts and side e †ects. As a result, from a regulatory perspective, we recommend strongly a reexamination of the FDAÏs current approach to ""fair balanceÏÏ and a redeÐnition of ""fair balanceÏÏ based on empirical research Ðndings. Until this is done, we agree with Smith (1999) , who argues that ""Pharmaceutical companies must now move beyond simply meeting FDAÏs fair balance requirements and seek the trust of consumers reading their ads. Copywriters need to select side e †ects that are most important for consumers to know about and put these risks into proper perspective.ÏÏ (p. 519)
